Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00885300
Recruitment Status : Completed
First Posted : April 21, 2009
Last Update Posted : April 21, 2009
Sponsor:
Information provided by:
Shiraz University of Medical Sciences

Brief Summary:
The purpose of this study is to investigate whether cloxacillin lock is effective in prevention of double lumen infection.

Condition or disease Intervention/treatment Phase
Double Lumen Infection Hemodialysis Drug: cloxacillin Drug: heparin Not Applicable

Detailed Description:
Double lumen infection is one of the causes of morbidity and mortality in hemodialysis patients. Many strategies used to prevent it and one of them is antibiotic lock. Thus we select chronic hemodialysis patients and divided them into 2 groups. One group received cloxacillin and heparin as catheter lock and the second group received only heparin lock.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients
Study Start Date : January 2008
Actual Primary Completion Date : July 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1
cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
Drug: cloxacillin
cloxacillin 100mg/ml as catheter lock at the end of hemodialysis

Drug: heparin
heparin 1000iu/ml as catheter lock at the end of hemodialysis

Active Comparator: 2
heparin 1000iu/ml as catheter lock at the end of hemodialysis
Drug: heparin
heparin 1000iu/ml as catheter lock at the end of hemodialysis




Primary Outcome Measures :
  1. catheter infection [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • hemodialysis for 3 months
  • at least 2 time dialysis/week

Exclusion Criteria:

  • active infection
  • acute renal failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00885300


Locations
Layout table for location information
Iran, Islamic Republic of
Shiraz University Hemodialysis Center
Shiraz, Fars, Iran, Islamic Republic of, o98-711
Sponsors and Collaborators
Shiraz University of Medical Sciences
Investigators
Layout table for investigator information
Study Chair: maryam pakfetart, assistant professor Shiraz nephro-urology research center

Publications:
Layout table for additonal information
Responsible Party: Office of Vice Chancellor for research in Shiraz UMS, Shiraz University of Medical Science
ClinicalTrials.gov Identifier: NCT00885300    
Other Study ID Numbers: 3705
First Posted: April 21, 2009    Key Record Dates
Last Update Posted: April 21, 2009
Last Verified: April 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Cloxacillin
Heparin
Calcium heparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents